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Airway macrophages provide a first line of host defense against a range of airborne pathogens, including
influenza virus. In this study, we show that influenza viruses differ markedly in their abilities to infect murine
macrophages in vitro and that infection of macrophages is nonproductive and no infectious virus is released.
Virus strain BJx109 (H3N2) infected macrophages with high efficiency and was associated with mild disease
following intranasal infection of mice. In contrast, virus strain PR8 (H1N1) was poor in its ability to infect
macrophages and highly virulent for mice. Depletion of airway macrophages by clodronate-loaded liposomes
led to the development of severe viral pneumonia in BJx109-infected mice but did not modulate disease severity
in PR8-infected mice. The severe disease observed in macrophage-depleted mice infected with BJx109 was
associated with exacerbated virus replication in the airways, leading to severe airway inflammation, pulmonary
edema, and vascular leakage, indicative of lung injury. Thymic atrophy, lymphopenia, and dysregulated
cytokine and chemokine production were additional systemic manifestations associated with severe disease.
Thus, airway macrophages play a critical role in limiting lung injury and associated disease caused by BJx109.
Furthermore, the inability of PR8 to infect airway macrophages may be a critical factor contributing to its
virulence for mice.
Airway macrophages (M) (AM), located at the interphase
between air and lung tissue, provide the first line of defense
following inhalation of airborne pathogens, including influenza
viruses. In addition to phagocytosis of virions and virus-in-
fected cells (16, 24), infection of AM represents an early event
in recognition of the virus by the innate immune system. Fol-
lowing intranasal (i.n.) infection of mice, influenza virus rep-
licates productively in type II epithelial cells lining the respi-
ratory tract. Murine M are also susceptible to influenza virus
infection and viral proteins are produced, but replication is
abortive and infectious progeny are not released (52, 69), al-
though recent studies suggest limited release from mouse M
exposed to highly pathogenic H1N1 and H5N1 viruses (44).
Following exposure to influenza virus, M synthesize and re-
lease proinflammatory cytokines and alpha/beta interferon (26,
27, 45, 55), which further limit viral replication and spread
within the respiratory tract. Inflammatory responses in the
airways must be tightly regulated to ensure rapid virus clear-
ance while avoiding excessive or chronic inflammation that
may damage the delicate tissue-air interface.
Liposome-encapsulated dichloromethylene diphosphonate
(clodronate or CL2-MDP) is taken up by phagocytic M and
accumulates in the cytosol, resulting in M death and deple-
tion (66). Administration of clodronate liposomes (CL-LIP)
has been widely used to selectively deplete airway M in
mouse models without affecting circulating monocytes (for ex-
amples, see references 4, 6, 8, 36, 47, 64, and 71). While
CL-LIP has been used predominantly in rodent models of
infection, it is noteworthy that CL-LIP treatment of pigs, a
natural host of influenza virus, resulted in enhanced morbidity
and mortality following infection with a human H1N1 subtype
virus (30). In murine studies, depletion of airway M prior to
influenza virus infection led to increased cytotoxic CD8 T-cell
responses in the lungs of virus-infected mice (71); however,
treatment with CL-LIP 48 h after infection was associated with
impaired CD8 T-cell responses (41). Furthermore, CL-LIP
treatment prior to intranasal infection of mice with a recom-
binant virus bearing the surface glycoproteins of the 1918 pan-
demic strain led to exacerbated disease and mortality (64).
Treatment of mice with CL-LIP has been associated with en-
hanced virus replication (41, 64, 71); however, the mechanisms
by which airway M initiate and modulate inflammatory re-
sponses and disease after influenza virus infection have not
been fully elucidated.
We observed in a previous study that influenza A virus
strains show marked differences in their abilities to infect mu-
rine M in vitro and implicated the M mannose receptor
(MMR) (CD206), a C-type lectin (46), in infectious virus entry
(48). Virus strain BJx109, a reassortant virus bearing the sur-
face glycoproteins of A/Beijing/353/89 (H3N2) and internal
components derived from A/PR/8/34 (H1N1) (PR8) bears a
highly glycosylated hemagglutinin (HA) molecule and was
shown to infect M to high levels, while the HA of PR8 is
poorly glycosylated and the virus infected M very poorly. In
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the current study, we demonstrate that intranasal infection of
mice with BJx109 leads to mild clinical disease, while infection
with an equivalent dose of PR8 leads to severe disease and
rapid death. Depletion of airway M by intranasal administra-
tion of CL-LIP prior to and during infection with influenza
viruses had little effect on the course of PR8 infection; how-
ever, BJx109 infection of M-depleted animals led to severe
disease and death. Severe disease was associated with en-
hanced virus replication, severe airway inflammation, and pul-
monary edema and vascular leakage, indicative of lung injury.
Together, these data demonstrate that airway M play a crit-
ical role in moderating disease severity during BJx109 infec-
tion. Furthermore, they suggest that the ability of PR8 to evade
infectious uptake by airway M is likely to be an important
factor contributing to its virulence for mice.
MATERIALS AND METHODS
Mice and viruses. C57BL/6 (B6) mice were bred and housed under specific-
pathogen-free conditions at the Department of Microbiology and Immunology,
University of Melbourne, Melbourne, Australia. Six- to 8-week-old male mice
were used in all experiments. The influenza A virus strains used in this study were
A/PR/8/34 (H1N1), as well as BJx109 (H3N2) and Phil/82-X (H3N2) which are
high-yielding reassortants of PR8 that bear the surface glycoproteins of A/Bei-
jing/353/89 (H3N2) and A/Philippines/2/82 (H3N2), respectively. Additional
wild-type (i.e., nonreassortant) viruses used were A/New York/55/2004 (H3N2),
A/Brisbane/9/2007 (H3N2), A/New Caledonia/20/1999 (H1N1), and A/Solomon
Islands/3/2006 (H1N1). The viruses were grown in 10-day embryonated hen’s
eggs by standard procedures and titrated on Madin-Darby canine kidney
(MDCK) cells as described previously (1).
The reassortant influenza viruses used in this study were generated by eight-
plasmid reverse genetics as previously described (43). The viruses were 7:1
reassortants consisting of either the PR8 (H1N1) backbone with the HA or
neuraminidase (NA) gene from BJx109 (H3N2; PR8-BJx109 HA and PR8-
BJx109 NA, respectively). The rescued viruses were recovered after 3 days and
amplified in the allantoic cavities of 10-day-old embryonated hens’ eggs.
Infection of mouse M and epithelial cells. Resident peritoneal exudate cell
(PEC) M and bronchoalveolar lavage (BAL) M were obtained from B6 mice
as previously described (48). PEC M (2.5 105 cells/well), BAL M (2.5 105
cells/well), MDCK cells (1  104 cells/well), or the LA-4 lung epithelial cell line
(3  104 cells/well) were seeded into 8-well glass chamber slides (LabTek; Nun)
and incubated overnight at 37°C. The cell density for seeding was chosen to
achieve similar densities of adherent cells from the different cell populations.
Cell monolayers were washed with serum-free medium and infected with 106
PFU of influenza virus as described previously (48). At 7 to 9 h postinfection, the
slides were washed in phosphate-buffered saline (PBS), fixed in acetone, and
stained with monoclonal antibody (MAb) clone MP3.10G2.IC7 (WHO Collab-
orating Centre for Reference and Research on Influenza, Melbourne, Australia),
specific for the nucleoprotein of type A influenza viruses, followed by fluorescein
isothiocyanate (FITC)-conjugated sheep anti-mouse immunoglobulin (Silenus,
Melbourne, Australia) and viewed under 40 magnification. The percentage of
fluorescent cells was determined in a minimum of 4 random fields with a mini-
mum of 200 cells counted for each sample. To determine the number of adherent
cells remaining after exposure to influenza virus, chamber slides were incubated
in 80% (vol/vol) acetone in water for 2 min at room temperature and then
stained with 10 g/ml propidium iodide (PI). Nuclear morphology was assessed,
intact nuclei were counted in 4 or more independent fields, and these data were
used to determine the percentage of viable cells.
To determine the titer of infectious virus present in supernatants from influ-
enza virus-infected LA-4 epithelial cells or PEC M, cell monolayers were
incubated with 106 PFU of BJx109 or PR8 virus for 60 min, washed three times
to remove free virus, and cultured at 37°C. At 2 and 24 h postinfection, the
supernatants were removed and the presence of infectious virus was determined
by standard plaque assay on MDCK cell monolayers in the presence of trypsin.
Infection and treatment of mice. Mice were anesthetized and infected with 105
PFU of influenza virus via the i.n. route in 50 l of PBS. The mice were weighed
daily and assessed for visual signs of clinical disease, including inactivity, ruffled
fur, labored breathing, and huddling behavior. Animals that had lost 25% of
their original body weight and/or displayed evidence of pneumonia were eutha-
nized. All research complied with the University of Melbourne’s Animal Exper-
imentation Ethics guidelines and policies. At various times after infection, mice
were euthanized, and the lungs, nasal tissues, brain, and heart were removed,
homogenized in PBS, and clarified by centrifugation. Titers of infectious virus in
the tissue homogenates were determined by standard plaque assay on MDCK
cells.
For depletion of airway M, mice were treated i.n. with 100 l of CL-LIP
while under light anesthesia with isoflurane. Clodronate was a kind gift of Roche
Diagnostics (Mannheim, Germany). It was encapsulated in liposomes as de-
scribed previously (65). Mice were treated 48 h prior to infection and every 72 h
thereafter, unless otherwise stated. Control animals received an equivalent vol-
ume of saline-loaded liposomes (SL-LIP) or PBS alone. In some experiments,
mice were treated with CL-LIP diluted to 30% in PBS. Depletion of airway M
in the BAL fluid and lung parenchyma was monitored by flow cytometry as
described below.
Recovery of leukocytes from mice. BAL cells and heparinized blood were
obtained as described previously (61). Lung cell suspensions were prepared by
incubating minced lung tissue with 2 mg/ml collagenase A (Roche Diagnostics,
Germany) for 30 min at 37°C and then pressing it through a fine wire mesh.
Samples were treated with Tris-NH4Cl (0.14 M NH4Cl in 17 mM Tris, adjusted
to pH 7.2) to lyse erythrocytes and washed in RPMI 1640 medium supplemented
with 10% fetal calf serum (FCS) (RF10). Cell numbers and cell viability were
assessed via trypan blue exclusion using a hemocytometer.
Differential leukocyte counts and flow cytometry. For flow cytometry analysis,
single-cell suspensions prepared from the blood, BAL fluid, and lung were
incubated on ice for 20 min with supernatants from hybridoma 2.4G2 to block Fc
receptors and then stained with appropriate combinations of FITC, phyco-
erythrin (PE), allophycocyanin (APC), or biotinylated monoclonal antibodies to
Ly6G (1A8), Gr-1 (RB6-8C5), CD45.2 (104), CD8a (53-6.7), CD4 (GK1.5),
B220 (RA3-6B2), NK1.1 (PK136), major histocompatibility complex (MHC)
class II (I-Ab; AF6-120.1), CD11b (M1/70), and CD11c (HL3) (all from BD
PharMingen) and F4/80 (BM8; Caltag Laboratory). Isotype controls were in-
cluded as appropriate to facilitate gating of leukocyte populations. Living cells
were analyzed by the addition of 10 g/ml PI to each sample, and the cells were
analyzed on a FACSCalibur flow cytometer. A minimum of 50,000 live cells
(PI) were collected. Airway M were identified as CD11chigh MHC class IIint
cells in lung cell suspensions and BAL fluids, while pulmonary dendritic cells
(pulDC) were identified as CD11chigh MHC class IIhigh (31).
Pulmonary histopathology. Lungs were inflated, fixed in 4% formaldehyde,
and processed in paraffin wax as previously described (62). Airway inflammation
of hematoxylin and eosin (H&E)-stained lung sections was evaluated on a sub-
jective scale of 0, 1, 2, 3, 4, or 5 (corresponding to none, very mild, mild,
moderate, marked, and severe inflammation, respectively) on randomized,
blinded sections by three independent readers (59). Tissues were graded for
peribronchiolar inflammation (around 3 to 5 small airways per section) and
alveolitis in multiple random fields per section. Immunoperoxidase staining of
paraffin-embedded lung sections was performed using polyclonal goat-anti influ-
enza A virus antibody (AbD Serotec, United Kingdom) and the goat Vectastain
ABC kit (Vector Laboratories) as previously described (62). Lung sections were
viewed on a Leica DMI3000 B microscope and photographed at 10 magnifi-
cation with a Leica DFC 490 camera running from the Leica application soft-
ware.
Assessment of lung edema. The lung wet-to-dry weight ratio was used as an
index of lung water accumulation during influenza virus infection. After eutha-
nasia of mice, the lungs were surgically dissected, blotted dry, and weighed
immediately (wet weight). The lung tissue was then dried in an oven at 60°C for
72 h and reweighed as dry weight. The ratio of wet to dry weight was calculated
for each animal to assess tissue edema as previously described (2, 70). The
concentration of protein in cell-free BAL supernatant was measured by adding
Bradford protein dye. A standard curve using bovine serum albumin (BSA) was
constructed, and the optical density (OD) was determined at 595 nm.
Cytokine bead array for the detection of inflammatory mediators. The levels
of gamma interferon (IFN-), tumor necrosis factor alpha (TNF-), interleukin
6 (IL-6), IL-10, IL-12.p70, and monocyte chemoattractant protein 1 (MCP-1) in
BAL supernatants and serum were determined with the use of a cytokine bead
array mouse inflammation kit (Becton Dickinson) according to the manufacturer’s
instructions. The detection limit for the assay was 20 pg/ml for all cytokines
tested.
Statistical analysis. For the comparison of two sets of values, Student’s t test
(two-tailed, two-sample equal variance) was used. When comparing three or
more sets of values, data were analyzed by one-way analysis of variance
(ANOVA), followed by posthoc analysis using Tukey’s multiple-comparison test.
For the analysis of histopathological data, a Kruskal-Wallis test (nonparametric)
was used, followed by the Dunn’s posthoc test. Survival proportions were com-
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pared using the Mantel-Cox log rank test. A P value of 0.05 was considered
statistically significant.
RESULTS
Influenza viruses differ in their abilities to infect murine
M, but not murine epithelial cells, in vitro. Initial studies
compared the infectivities of influenza virus strains BJx109 and
PR8 for M and epithelial cells using primary cells and rep-
resentative cell lines. Consistent with our previous findings
(50), primary M isolated from PECs or BAL fluids via ad-
herence to glass chamber slides were highly susceptible to
infection by BJx109, but not by PR8 (Fig. 1A). In contrast,
BJx109 and PR8 infected epithelial cells, including a mouse
airway epithelial cell line (LA-4), to equivalent levels, indicat-
ing there is no defect in the ability of PR8 to infect mammalian
cells per se (Fig. 1A). As both HA and NA glycoproteins can
modulate the efficiency of virus infection of target cells (67), we
used engineered PR8 viruses expressing either the HA (PR8-
BJx109 HA) or NA (PR8-BJx109 NA) of BJx109 to demon-
strate that efficient infection of airway M was associated with
expression of the BJx109 HA, not the NA (Fig. 1B). In con-
trast, expression of either PR8 or BJx109 HA did not alter the
ability of engineered viruses to infect LA-4 airway epithelial
cells.
We next determined the consequences of exposing M or
epithelial cells to BJx109 or PR8 virus. First, we determined
the number of adherent PEC M, BAL M, or murine LA-4
epithelial cells that remained adherent 24 h after exposure to
106 PFU of BJx109, PR8, or medium alone (mock infection).
As seen in Fig. 1C, few adherent LA-4 epithelial cells could be
detected 24 h after exposure to either BJx109 or PR8 virus.
Exposure of M to BJx109 virus led to a marked reduction in
cell adherence (30%); however, exposure of M to an equiv-
alent dose of PR8 had little effect on the proportion of adher-
ent cells (	80%). Consistent with these findings, visual exam-
ination of monolayers of primary M 24 h postinfection
demonstrated that 	80% of cells exposed to BJx109 exhibited
evidence of cytopathic effect (CPE) (characterized by rounding
of adherent cells, cytoplasmic granularity, cells floating in the
supernatant, and cell destruction) while 10% CPE was ob-
served in M monolayers exposed to an equivalent dose of
PR8 (data not shown). LA-4 epithelial cells exposed to either
BJx109 or PR8 exhibited 	90% CPE at 24 h postinfection.
We next compared the abilities of BJx109 and PR8 to rep-
licate productively in primary M or in airway epithelial cells.
For these experiments, cell monolayers were exposed to equiv-
alent doses of either BJx109 or PR8 and washed to remove
unbound virus, and the amount of infectious virus present in
the cell supernatants was determined at 2 h (to determine
FIG. 1. Influenza viruses BJx109 and PR8 differ in their abilities to
infect M, but not epithelial cells. (A) Monolayers of mouse PEC M,
BAL M, MDCK cells, and LA-4 epithelial cells were infected in cham-
ber slides with 106 PFU of BJx109 or PR8, as described in Materials and
Methods. At 6 to 8 h postinfection, cells were fixed and stained via
immunofluorescence for expression of influenza A virus nucleoprotein
(NP). The mean percent infection (plus 1 standard deviation [SD]) from
a minimum of 4 independent fields per chamber is shown for a represen-
tative experiment, and infection of M by PR8 was significantly reduced
compared to BJx109 in 4 independent experiments (P  0.01; one-way
ANOVA). (B) BAL M or LA-4 epithelial cells were infected with 106
PFU of BJx109 or PR8 or with reverse-engineered viruses expressing 7
genes derived from PR8 with the HA (PR8-BJx109 HA) or the NA
(PR8-BJx109 NA) of BJx109 and stained by immunofluorescence at 8 h
postinfection. The data from a representative experiment are shown, and
infection of M with PR8 or PR8-BJx109 NA was significantly different
from that with BJx109 in 3 independent experiments (P  0.01; one-way
ANOVA). (C) Numbers of adherent PEC M and LA-4 cells 24 h after
exposure to influenza viruses. Monolayers of PEC M and LA-4 cells
were infected in chamber slides with 106 PFU of BJx109 or PR8 or mock
infected with medium alone. At 24 h postinfection, cells were fixed and
stained via immunofluorescence for nucleic acids using PI. Nuclear mor-
phology was assessed, and intact nuclei were counted in 4 independent
fields. The data are expressed as a percentage of the number of nuclei
counted in mock-infected controls. The error bars represent 1 SD. The
data from a representative experiment are shown, and numbers of adher-
ent M exposed to BJx109 were significantly reduced compared to PR8 in
3 independent experiments (P  0.01; one-way ANOVA). (D) Release
of infectious virus from influenza virus-infected PEC M and LA-4 cells.
Monolayers of cells were infected with 106 PFU of BJx109 or PR8, and
samples of supernatant were removed at 2 h (to detect residual virus
inoculum) and 24 h (to detect newly synthesized virions released from
infected cells) postinfection. The samples were assayed for infectious
virus by plaque assay on MDCK cells, and the fold increase in infec-
tious virus was calculated by dividing the viral titer obtained at 24 h by
that obtained at 2 h. The data represent the mean (plus 1 SD) from 3
independent experiments.
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residual levels of infectious virus) and 24 h (to determine levels
released following virus replication) postinfection. Exposure of
LA-4 epithelial cells to BJx109 or PR8 led to productive virus
replication and amplification, as noted from the increased ratio
of infectious virus in supernatants at 2 and 24 h postinfection
(Fig. 1D). In contrast, exposure of PEC or BAL M to BJx109
or PR8 was not associated with release of infectious virus
between 2 h and 24 h postinfection, consistent with previous
reports that infection of murine M by influenza virus led to
abortive virus replication (52).
Following intranasal infection, BJx109 and PR8 differ
markedly in their virulence for mice. Infection of M by in-
fluenza virus is likely to represent an important innate immune
response, as viral replication is abortive and no infectious virus
is released (52) (Fig. 1D). Given the marked differences in the
capacities of virus strains BJx109 and PR8 to infect murine
M, it was of interest to compare the virulence of the 2 virus
strains following intranasal inoculation of B6 mice. Intranasal
inoculation of mice with 105 PFU of BJx109 was not associated
with significant weight loss over a 10-day monitoring period
(Fig. 2A, top), and all mice survived the infection (Fig. 2A,
bottom). Furthermore, no clinical signs of disease (lethargy,
ruffled fur, or labored breathing) were noted. Intranasal inoc-
ulation with an equivalent dose of PR8 led to rapid weight loss,
and all mice succumbed 4 to 5 days postinfection. At the time
of death, PR8-infected mice showed hunched posture, leth-
argy, and labored breathing, consistent with development of
viral pneumonia. We used reverse-genetics viruses to demon-
strate that expression of the HA, but not the NA, of BJx109 on
a PR8 “backbone” was sufficient to ameliorate the severe dis-
ease associated with PR8 infection. As seen in Fig. 2B, mice
infected with 105 PFU of PR8-BJx109 NA lost weight rapidly
(top) and succumbed to infection (bottom), while mice in-
fected with PR8-BJx109 HA showed no weight loss or signs of
disease.
A range of additional virus strains were found to infect M
efficiently (A/New York/55/2004 [H3N2], A/Brisbane/9/2007
[H3N2], A/New Caledonia/20/1999 [H1N1], and A/Solomon
Islands/3/2006 [H1N1] at 87% 
 3%, 95% 
 1%, 83% 
 2%,
and 85% 
 3% infected cells, under conditions identical to
those described for Fig. 1A and B), and infection of mice with
105 PFU of each virus strain was not associated with weight
loss or disease over a 10-day monitoring period (data not
shown). Together, these findings suggest that internalization
and nonproductive infection of airway M could be critical
factors limiting the severity of disease induced by BJx109.
Selective depletion of M from airways and lung paren-
chyma following treatment with CL-LIP. To deplete M from
the airways and the lung, naïve mice were treated with 100 l
of CL-LIP via the intranasal route, and the efficacy of this
procedure was assessed after 2 days via flow cytometric analysis
of BAL fluid or lung tissue, respectively. Control mice received
an equivalent volume of SL-LIP or PBS alone. Based on the
studies of Kirby et al., AM were identified as CD11c MHC-
IIint cells and pulDC as CD11c MHC-IIhigh (31), and repre-
sentative dot plots in Fig. 3A show selective depletion of airway
M in BAL fluid of CL-LIP-treated mice. Compared to SL-
LIP-treated controls, CL-LIP treatment 2 days prior to analysis
led to a 60 to 80% reduction in the numbers of airway M in
BAL fluid or lung tissue (Fig. 3B) from naive animals 48 h after
treatment. While CL-LIP treatment was effective in depleting
airway M, it did not deplete CD11c MHC-IIhigh pulDC in
FIG. 2. Virulence of influenza viruses for C57BL/6 mice. Groups of 5 mice were infected with 105 PFU of BJx109 or PR8 (A) or reverse-
genetics virus PR8-BJx109 HA or PR8-BJx109 NA (B) via the intranasal route. Control mice received an equivalent volume of PBS. (Top) Mice
were weighed daily, and the results are expressed as the mean percent weight change of each group
 standard error of the mean (SEM) compared
to the weight immediately prior to infection. Animals displaying evidence of pneumonia and/or having lost 	25% of their original body weights
were euthanized. (Bottom) Survival of mice following intranasal infection with influenza viruses. The data shown are from one experiment and are
representative of two or more independent experiments. The P values for survival proportions were obtained using the Mantel-Cox log rank test.
BJx109 versus PR8, P  0.01, and PR8-BJx109 HA versus PR8-BJx109 NA, P  0.01, in 2 independent experiments.
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the airways (Fig. 3C). The numbers of pulDC in BAL fluid of
CL-LIP-treated mice were actually enhanced compared to
PBS- or SL-LIP-treated controls, while the numbers of lung
pulDC were similar to those from control animals (Fig. 3C).
Intranasal treatment of naïve mice with CL-LIP did not affect
the numbers of circulating monocytes/macrophages (F4/80 or
CD11chigh MHC class IIint), DC (CD11chigh MHC class IIhigh),
neutrophils (Ly6Ghigh), or B220 lymphocytes when examined
2 days after treatment (data not shown), confirming local de-
pletion of airway M using this treatment regime.
Depletion of airway M prior to and during influenza virus
infection. Intranasal infection with influenza viruses is known
to induce recruitment of leukocytes, including M, to the air-
ways (11, 25). To maintain depletion of airway M throughout
the course of infection, we treated mice at day 2 relative to
infection and every 3 days thereafter (i.e., days 2, 1, 4,
and 7). Preliminary experiments established that treatment
of mice with CL-LIP at days 2, 1, 4, and 7 relative to
intranasal inoculation with PBS at day 0 (i.e., mock infection)
did not result in any signs of overt illness (weight loss, hunched
posture, or labored breathing) compared to untreated mice or
mice treated identically with SL-LIP (data not shown). Mice
treated with CL-LIP at days 2, 1, and 4 relative to infec-
tion with 105 PFU of BJx109 lost weight rapidly, and all mice
succumbed to disease by day 7 postinfection (Fig. 4A). In
contrast, control animals infected with BJx109 and treated with
SL-LIP or PBS showed no significant weight loss or disease. A
similar phenomenon was observed when mice were infected
with 105 PFU of Phil/82-X, a reassortant virus bearing the HA
and NA of A/Philippines/2/82 and the internal components of
PR8. In vitro, Phil/82-X infected murine M efficiently (83%

6% infected M, under conditions identical to those described
for Fig. 1A) and did not induce weight loss or disease in mice
following intranasal inoculation, although CL-LIP treatment
led to severe disease and death (Fig. 4B). Mice treated with
PBS, SL-LIP, or CL-LIP and infected with PR8 all lost weight
rapidly and were euthanized 4 to 5 days postinfection (Fig. 4C).
PR8 is a highly mouse-adapted strain, and numerous viral
genes have been implicated in modulating disease severity
(68); however, our findings with BJx109 and Phil82-X, both of
which contain internal components derived from PR8, demon-
strate that the HA/NA glycoproteins are of critical importance
in enhancing the ability of the PR8 reassortant viruses to infect
airway M and in ameliorating disease severity in mice.
At the time these studies were being conducted, Pribul et al.
demonstrated that intranasal treatment of mice with 30% CL-
LIP diluted in PBS led to effective depletion of airway M with
minimal associated lung inflammation (47). Our data con-
firmed these findings, as treatment of mice at day2 with 30%
CL-LIP reduced the percentage of airway M by approxi-
mately 70% relative to SL-LIP (SL-LIP  31.8 
 4.2; 100%
CL-LIP  2.0 
 0.5; 30% CL-LIP  4.9 
 1.9; all data are
percent CD11C MHC-IIint cells out of total BAL cells at day
0). Furthermore, treatment of mice with 30% CL-LIP at days
2, 1, and 4 relative to infection with 105 PFU of BJx109
induced weight loss and mortality similar to that observed
following treatment with 100% CL-LIP (data not shown).
Thus, treatment with both 100% and 30% CL-LIP was in-
cluded in all subsequent analysis for BJx109-infected mice.
Effect of M depletion on virus replication in the airways
during BJx109 infection of mice. We next investigated factors
contributing to the severity of clinical disease observed in M-
depleted mice following infection with BJx109. All subsequent
analyses focused on day 7 postinfection, the time at which
CL-LIP-treated mice succumbed to disease. First, we deter-
mined the viral loads in the respiratory tracts of BJx109-in-
fected animals. By day 7 postinfection, infectious virus had
been cleared from the airways of BJx109-infected mice treated
with either PBS or PBS-CL (Fig. 5A); however, 100- to 1,000-
fold more virus was recovered in homogenates prepared from
nasal tissues or lungs of mice treated with 30% or 100% CL-
LIP. Immunohistochemical localization demonstrated abun-
dant viral antigen in epithelial cells lining the bronchioles and
large airways and throughout the alveoli of mice treated with
100% CL-LIP (Fig. 5B, ii) and 30% CL-LIP (Fig. 5B, iii), but
not in PBS-treated (data not shown) or SL-LIP-treated (Fig.
5B, i) controls. Moreover, the distribution of viral antigen in
the lungs of CL-LIP-treated mice infected with BJx109 was
FIG. 3. Depletion of lung macrophages via treatment with clodro-
nate-loaded liposomes. Groups of 5 naïve mice were treated with 100
l of CL-LIP via the intranasal route. Control mice received an equiv-
alent volume of PBS or SL-LIP. At 48 h posttreatment, the mice were
killed, and the cell types present in BAL fluid and lungs were deter-
mined. (A) Representative dot plots of BAL cells from mice treated
with PBS, SL-LIP, or CL-LIP. AM were identified as CD11c MHC
class IIint and pulDC as CD11c MHC class IIhigh by flow cytometry.
Total numbers of AM (B) and pulDC (C) in the BAL fluid and lung
were determined by flow cytometry. *, CL-LIP-treated mice were
significantly different from SL-LIP-treated controls (P 0.05; one-way
ANOVA).
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very similar to that observed in the lungs of mice infected with
a similar dose of PR8 (Fig. 5B, iv). Thus, following depletion of
airway M via CL-LIP treatment, BJx109 is “redirected” to
infect epithelial cells of the respiratory tract, thereby allowing
productive virus replication and amplification in the airways.
By removing airway M, virus strain BJx109 induces clinical
disease and pathogenesis similar to those of the mouse-
adapted PR8 strain.
Severe clinical disease following BJx109 infection of M-
depleted mice is associated with excessive inflammation of the
airways. Excessive or dysregulated inflammation of the airways
has been associated with severe viral pneumonia during influ-
enza virus infections of humans (12), macaques (32), and mice
(44, 60, 64). Consistent with this, the pulmonary pathology
observed in lung sections from BJx109-infected mice treated
with either 100% (Fig. 6A, ii) or 30% (Fig. 6A, iii) CL-LIP was
markedly more severe than that of SL-LIP-treated (Fig. 6A, i)
or PBS-treated (data not shown) controls and more similar to
the inflammation observed in PR8-infected mice at day 5
postinfection (Fig. 6A, iv). When scored in a blinded manner
by 3 independent readers, both peribronchiolar inflammation
and alveolitis were markedly enhanced in the lungs from virus-
infected mice treated with 100% or 30% CL-LIP compared to
PBS- or SL-LIP-treated controls (Fig. 6B).
We next characterized inflammatory cells and soluble medi-
ators present in BAL fluids from M-depleted mice to gain
insight into factors contributing to the severe pulmonary im-
munopathology observed in these animals. Total BAL cell
numbers were markedly increased in BJx109-infected mice
treated with 100% or 30% CL-LIP, with numbers of neutro-
phils, NK cells, pulDC, B220 cells, CD4 T cells, and CD8
T cells all significantly enhanced in M-depleted mice com-
pared to SL-LIP-treated controls (Fig. 6C). In particular, neu-
trophil and CD8 T-cell numbers were 3- to 5-fold higher in
BAL fluid from M-depleted mice. Of note, airway M
(CD11c MHC-IIint) were reduced by 60 to 75% in CL-LIP-
treated mice (20.2%
 6.9%, 12.2%
 6.7%, 1.5%
 0.4% and
1.3% 
 0.3% of total BAL cells for mice treated with PBS,
SL-LIP, 30% CL-LIP, or 100% CL-LIP, respectively), indicat-
ing effective M depletion at day 7 postinfection, despite the
large numbers of inflammatory cells recruited to the airways of
CL-LIP-treated mice.
It has been postulated that excessive or dysregulated pro-
duction of inflammatory mediators may contribute to lung
pathology during influenza virus infection (9, 73). At day 7
postinfection, the severe pulmonary inflammation observed in
CL-LIP-treated mice infected with BJx109 was associated with
a significant enhancement in local (airway) production of
MCP-1 (BAL fluid, 20.2 
 8.1 and 32.5 
 6.1 pg/ml, and
serum, 10.9 
 2.4 and 52.0 
 30.3 pg/ml for SL-LIP and 100%
CL-LIP, respectively; P 0.05; one-way ANOVA). In general,
levels of IL-6 were enhanced in BAL fluid from M-depleted
mice; however, levels in the CL-LIP-treated groups were highly
variable, and differences were not significant (BAL fluid,
30.2 
 26.7 and 251.4 
 243.7 pg/ml for SL-LIP and 100%
CL-LIP, respectively; P 	 0.05; one-way ANOVA). Levels of
TNF-, IFN-, IL-10, and IL-12 were not significantly elevated
in the BAL fluid of M-depleted mice compared to SL-LIP-
treated controls (data not shown).
Airway M have been implicated in susceptibility to second-
ary bacterial infections following influenza virus infections (28,
34, 58). To determine if the severe disease observed in CL-
LIP-treated mice infected with BJx109 was related to second-
ary bacterial pneumonia, BAL supernatants recovered at day 7
postinfection were plated onto nutrient agar and horse blood
agar, and after incubation at 37°C for 3 days, the number of
FIG. 4. Effect of macrophage depletion on the course of disease following intranasal infection with influenza viruses. Groups of 5 B6 mice were
depleted of macrophages via i.n. treatment with CL-LIP 48 h prior to infection with 105 PFU of BJx109 (A), Phil/82-X (B), or PR8 (C) and every
3 days thereafter. Control groups received an equivalent volume of SL-LIP or PBS alone. (Top) The mice were weighed daily, and the results are
expressed as the mean percent weight change of each group (
SEM) compared to the original body weight. (Bottom) Animals that had lost25%
of their original body weight and/or presented with evidence of pneumonia were killed. The P values for survival proportions were obtained from
2 independent experiments using the Mantel-Cox log rank test. BJx109, CL-LIP versus SL-LIP, P  0.01; Phil/82-X, CL-LIP versus SL-LIP, P 
0.01; and PR8, CL-LIP versus SL-LIP, P 	 0.05.
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CFU was determined. CFU counts were low (0 to 500 CFU/ml
of BAL fluid for all groups) and not statistically different be-
tween BJx109-infected mice treated with PBS, SL-LIP, or CL-
LIP, thereby excluding secondary bacterial infection as a major
factor associated with disease.
BJx109 infection of M-depleted mice is associated with
vascular leakage and pulmonary edema. Viral or inflammatory
lung injury can lead to acute lung injury, characterized by
alveolar barrier dysfunction and subsequent accumulation of
protein-rich fluid in the alveolar compartment (42, 72). Con-
sistent with this, total protein levels in cell-free BAL fluid were
approximately 4-fold higher in M-depleted mice than in SL-
LIP-treated controls (Fig. 7A). Furthermore, the lungs of M-
depleted mice were visibly enlarged and showed a marked
enhancement in the wet/dry ratio (Fig. 7B), a measure of
extravascular water. Together, these data indicate that the
severe clinical disease observed following M depletion of
BJx109-infected mice was associated with vascular leakage and
lung edema, indicative of acute respiratory distress syndrome
(ARDS)-like respiratory failure (18, 72).
Systemic responses in M-depleted mice infected with
BJx109. Systemic manifestations, such as myocarditis, leuko-
penia, and thymic atrophy, have been associated with severe
clinical disease during influenza virus infections (13, 17, 35, 54).
First, infectious virus was not consistently recovered from the
hearts and brains of CL-LIP-treated mice, and we did not detect
evidence of edema (wet/dry ratio) in hearts recovered from M-
depleted mice, suggesting that myocarditis was not a major factor
contributing to severe disease. We did, however, record marked
reductions in the numbers of total leukocytes in the blood of
CL-LIP-treated mice at day 7 postinfection (Fig. 8A). While neu-
trophil numbers were not reduced, circulating B220 cells and
T-cell receptor -positive (TCR-) T cells were depleted, in-
cluding both CD4 and CD8 T-cell compartments.
In addition, the thymi of CL-LIP-treated mice infected with
BJx109 showed a significant reduction in total cellularity, and
flow cytometry analysis indicated a specific reduction in the
number of double-positive (DP) thymocytes recovered from
M-depleted mice (Fig. 8B). It should be noted that in pre-
liminary experiments we established that CL-LIP treatment of
naïve animals was not associated with a reduction in total cells
or DP cells in the thymi of naïve animals (data not shown).
DISCUSSION
In this study, we investigated factors involved in modulating
the severity of disease in a mouse model of influenza virus
infection. More specifically, we demonstrated that airway M
play a critical role in ameliorating disease severity following
intranasal infection of mice with virus strain BJx109. In vitro
studies demonstrated that BJx109 was able to infect murine
M, including airway M, with high efficiency. Furthermore, in
vivo depletion of airway M during BJx109 infection of mice
led to viral pneumonia and death. In contrast, virus strain PR8
was inefficient in its ability to infect murine M in vitro, and the
severe disease noted in PR8-infected mice was not further
exacerbated when airway M were depleted. M depletion
during BJx109 infection was associated with enhanced virus
replication, pulmonary inflammation, lung edema, and vascu-
lar leakage, indicating that airway M control infection and
limit the development of lung injury and ARDS during influ-
enza virus infection of mice.
In both humans and mice, bronchial and alveolar epithelial
cells represent the major targets for influenza virus infection
and subsequent amplification (5). Infection is initiated follow-
ing attachment of the viral HA to sialic acid moieties on cell
surface glycoproteins and/or glycolipids, although the specific
host cell molecules that mediate this process are yet to be
defined. While H3N2 and H1N1 subtype viruses can differ
markedly in the types and/or linkages bound by their respective
HA glycoproteins (53, 56), BJx109 and PR8 infected murine
airway epithelial cells equally well in vitro (Fig. 1A), and similar
levels of newly synthesized virions were released from virus-
infected cells by 24 h postinfection (Fig. 1D).
Major differences were noted, however, in the course of
disease (Fig. 2) and in the distribution of viral antigen in airway
FIG. 5. Depletion of airway macrophages during BJx109 infection
is associated with enhanced virus replication in the airways. Groups of
5 B6 mice were depleted of macrophages via i.n. treatment with 100%
CL-LIP or 30% CL-LIP 48 h prior to infection with 105 PFU of BJx109
and every 3 days thereafter. Control groups received an equivalent
volume of SL-LIP or PBS alone. The mice were killed and analyzed at
day 7 postinfection. (A) Lungs and nasal tissues were homogenized,
and virus titers were determined by plaque assay on MDCK cells. The
bars represent mean viral titers plus 1 SD. The detection limit for the
plaque assays is indicated as a dotted line. *, virus titers from 100%
CL-LIP- and 30% CL-LIP-treated mice that were significantly higher
than those from SL-LIP-treated control animals (P  0.01; one-way
ANOVA). (B) Distribution of viral antigen in the lungs of macro-
phage-depleted or control mice. Representative images are shown at
10 magnification. Cells positive for viral antigen are stained brown,
and the arrows indicate representative areas of intense antigen
staining.
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FIG. 6. Depletion of airway macrophages during BJx109 infection is associated with enhanced pulmonary inflammation. Groups of 5 B6 mice
were depleted of airway macrophages via i.n. treatment with 100% or 30% CL-LIP 48 h prior to infection with 105 PFU of BJx109 and every 3
days thereafter. Control groups received an equivalent volume of SL-LIP or PBS alone, and all mice were killed and analyzed at day 7 postinfection.
(A) Representative images of inflammation in lung sections following H&E staining. Mice infected with 105 PFU of PR8 and analyzed at day 5
postinfection are included for comparison. The images are shown at 10 magnification. (B) Histopathological scores for lung sections from
BJx109-infected mice. Lung sections were scored blind for alveolitis and peribronchiolar inflammation from 0 to 5. The data shown represent scores
from individual mice (as indicated by circles) and median values (as indicated by bars) obtained from 1 of 3 independent readers. Samples were
compared for statistical significance using the Kruskal-Wallis test (nonparametric). For each reader, significant differences were observed in
immunopathology scores between CL-LIP-treated mice (100% or 30%) and SL-LIP-treated mice (P  0.05). (C) Inflammatory cells present in
BAL fluid of BJx109-infected mice. BAL cells recovered from the airspaces of the lung were examined by flow cytometry for total numbers of
CD45 inflammatory cells, as well as for leukocyte subsets, including neutrophils (Gr-1high), NK cells (NK1.1 TCR-), CD4 cells (CD4),
CD8 cells (CD8), and pulDC (CD11c MHC class IIhigh). A minimum of 50,000 living cells (PI) were collected and analyzed for each mouse.
*, cell numbers from 100% CL-LIP- and 30% CL-LIP-treated mice that were significantly higher than those from SL-LIP-treated control animals
(P  0.05; one-way ANOVA).
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epithelial cells of BJx109- versus PR8-infected mice (Fig. 5B, i
and iv, respectively), indicating that components of the innate
immune system limit infection and/or amplification of BJx109
in the lung. BJx109 is highly sensitive to neutralization and
destruction by the collectin SP-D, while PR8 is largely resistant
(23, 49). SP-D is found in lung fluids and other respiratory
secretions lining the airways (10, 40, 49) and binds to mannose-
rich glycans expressed on the HA and NA of influenza viruses
(23, 39, 49) to aggregate virions, neutralize virus infectivity,
and opsonize virus for its interactions with neutrophils (21, 22).
The related collectin mannose-binding lectin (MBL) may also
transude from the circulation into the inflamed lung during
influenza virus infections (49). The potent antiviral activity of
SP-D (and related innate immune proteins) is likely to inhibit
attachment and/or entry of BJx109 into bronchial and alveolar
epithelial cells and may also hinder release and spread of
BJx109 from virus-infected epithelial cells following productive
virus replication. In contrast, PR8 appears to be largely resis-
tant to these host defenses and so replicates extensively in
epithelial cells throughout the respiratory tract.
In contrast to epithelial cells, M did not support productive
viral replication, as there was no increase in levels of infectious
virus released from primary M exposed to either BJx109 or
PR8 by 24 h postinfection (Fig. 1D). Also, the receptors me-
diating infectious entry into M are different from epithelial
cell receptors, as the MMR, implicated in infection of murine
M by influenza viruses (49), is not expressed on epithelial cell
populations. Exposure of M to influenza virus has been
shown to induce potent release of proinflammatory cytokines
and chemokines (26, 27, 45, 55), and these may play a critical
role in limiting virus infection. Such responses must be tightly
regulated, as dysregulated cytokine responses have been asso-
ciated with immunopathology and disease severity during in-
fections with H5N1 (9, 73) and 1918 (32) pandemic viruses.
While both M and epithelial cells respond to influenza virus
infection by releasing soluble mediators, the spectra of chemo-
kines and cytokines produced differ markedly between cell
types (reviewed in reference 29). Depletion of airway M prior
to respiratory syncytial virus (RSV) infection of mice led to
profound inhibition of the early release of inflammatory cyto-
kines in the airways but had little effect on disease severity,
weight loss, or lung function (47). In the mouse model of
influenza virus infection, it is likely that M depletion may also
inhibit early protective cytokine responses to BJx109, and the
absence of such responses would contribute to the uncon-
trolled virus replication observed in the lungs of CL-LIP-
treated animals (Fig. 5). Interestingly, local production of
MCP-1 was markedly enhanced in the later stages of infection
(data not shown), suggesting that dysregulated cytokine pro-
duction by infected epithelial cells and/or additional leukocytes
recruited to the airways may also contribute to the pulmonary
inflammation, lung injury and severe disease observed at day 7
postinfection. The inability of PR8 to infect airway M (Fig.
1A) suggests the virus is also likely be poor in its ability to
induce early inflammatory mediators from M; consequently,
the pathogenesis of BJx109 in M-depleted mice is rather
similar to that of PR8 in untreated animals.
Intranasal infection of mice with BJx109 induced very mild
disease, while infection of M-depleted mice led to severe
disease and death. A number of factors have been proposed to
contribute to the severity of influenza disease, including un-
controlled virus replication and spread (19, 38), secondary
bacterial infection (7, 20, 57), and excessive or dysregulated
inflammatory responses (44, 73). In humans, severe influenza
virus infections have been associated with histopathological
lesions indicative of ARDS (18), a condition in which the
integrity of the lung alveolar-capillary barrier may be damaged,
leading to flooding of the alveoli with plasma liquid and pro-
teins. Depletion of airway M led to enhanced virus replica-
tion in the airways during BJx109 infection, and this in turn was
associated with hallmark features of ARDS, such as severe
pulmonary inflammation (Fig. 6), alveolar leakage (Fig. 7A),
and lung edema (Fig. 7B), similar to that described in a mouse
model of ARDS infection induced by H5N1 infection (72).
Together, these findings demonstrate a critical role for airway
M in containing early virus replication and in ameliorating
epithelial injury and vascular permeability in the lungs of virus-
infected mice.
In animal models of influenza virus infection, we and others
(30, 64, 71) have demonstrated the importance of airway M in
limiting virus replication and disease severity. While infection
of mouse airway M by RSV is also abortive (14), depletion of
airway macrophages prior to RSV infection has been associ-
FIG. 7. Vascular leakage and pulmonary edema in macrophage-
depleted mice infected with BJx109. Groups of 5 B6 mice were de-
pleted of macrophages via i.n. treatment with 100% or 30% CL-LIP
48 h prior to infection with 105 PFU of BJx109 and every 3 days
thereafter. Control groups received an equivalent volume of SL-LIP or
PBS alone, and all mice were killed and analyzed at day 7 postinfec-
tion. (A) Total protein concentrations in cell-free BAL supernatants.
*, 100% CL-LIP- and 30% CL-LIP-treated mice were significantly
different from SL-LIP control mice (P  0.01; one-way ANOVA).
(B) Lung wet-to-dry ratios as an assessment of pulmonary edema. The
data are representative of at least 2 independent experiments. *, 100%
CL-LIP- and 30% CL-LIP-treated mice were significantly different
from SL-LIP-treated control mice (P  0.01; one-way ANOVA).
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ated with exacerbated virus replication and airway occlusion
(51) and with reduced early inflammatory cytokines and NK
cells in the airways (47), suggesting that factors such as the
virus strain, inoculum dose, and mouse strain can also influ-
ence the disease outcome. Despite these differences, airway
macrophages play a clear role in viral clearance and resolution
of inflammation associated with respiratory viruses.
In the context of influenza virus infections, mononuclear
phagocytes recruited to inflamed lung tissues in a CCR2-de-
pendent manner (26) can contribute to alveolar epithelial cell
apoptosis by the release of tumor necrosis factor-related apo-
ptosis-inducing ligand (TRAIL) in acute viral pneumonia,
thereby leading to alveolar damage and vascular leakage (25).
Thus, while “resting” airway M are the first immune cells to
sense and respond to influenza virus infection, the subsequent
recruitment and activation of inflammatory Mmust be tightly
controlled during infection to promote clearance of virus-in-
fected epithelial cells while minimizing excessive damage and
associated vascular leakage into the airways. Early and exces-
sive macrophage infiltration has also been associated with se-
vere lung pathology and disease following infection of mice
with highly pathogenic H1N1 and H5N1 viruses (44).
A recombinant virus expressing the HA and NA glycopro-
teins of the 1918 pandemic virus was shown to be highly viru-
lent for mice, and depletion of airway M during infection was
associated with increased virus replication in the lungs (and
spread to the brain), as well as significant reductions in cyto-
kines and chemokines in the airways at day 5 postinfection
(64). The exceptional virulence of the 1918 pandemic virus is
likely due to the constellation of virus genes; however, the HA
and NA have been implicated in contributing to its pathoge-
nicity in mice (33, 63, 64). In contrast to PR8, the 1918 virus
can infect and replicate productively to some degree in mouse
M (44), and consistent with these findings, M depletion
further exacerbated disease in mice infected with the recom-
binant virus expressing the HA/NA derived from the 1918
strain (64). The reduced proinflammatory mediators in the
lungs of macrophage-depleted mice led the authors to propose
that the HA/NA glycoproteins of the 1918 virus induced high
levels of cytokines and chemokines in the lung and that airway
M were required to facilitate this process. Together, these
findings suggest that mechanisms underlying the virulence of
distinct influenza virus strains for mice can be very different.
The PR8 strain is highly adapted to growth in the mouse
lung and induces interstitial pneumonia similar to that ob-
served in human cases of viral pneumonia (15, 37). Multiple
factors have been proposed to contribute to the virulence of
PR8, including its high growth capacity, a function of the in-
ternal genes of PR8 that led to its use is the generation of
high-yielding reassortant strains with vaccine potential (3). In
addition, we propose that during adaptation to growth in the
mouse lung, viruses may also have been selected for virulence
by virtue of their ability to evade airway M. Direct compar-
ison of inflammatory responses to BJx109 and PR8 in vivo are
complicated by the rapid growth of PR8 in the airways (50);
however, our current findings that BJx109 induces a disease
FIG. 8. Lymphopenia and thymic atrophy in macrophage-depleted mice infected with BJx109. Groups of 5 B6 mice were depleted of
macrophages via i.n. treatment with 30% or 100% CL-LIP 48 h prior to infection with 105 PFU of BJx109 and every 3 days thereafter. Control
groups received an equivalent volume of SL-LIP or PBS alone. All mice were killed and analyzed at day 7 postinfection. (A) Viable-cell counts
were performed on whole blood to determine total leukocyte numbers, and flow cytometry was used to determine total numbers of T cells
(TCR-), CD4 T cells (CD4 TCR-), and CD8 T cells (CD8 TCR). *, cell numbers from 100% CL-LIP- and 30% CL-LIP-treated mice
that were significantly lower than those from SL-LIP-treated control animals (P 0.05; one-way ANOVA). (B) Viable-cell counts were performed
on single-cell suspensions prepared from mouse thymi (total cells), and flow cytometry was used to determine the number of double-negative
(CD4 CD8) (DN), DP (CD4 CD8), and single-positive (CD4 or CD8) (SP) thymocytes present. *, cell numbers from macrophage-
depleted mice (100% CL-LIP and 30% CL-LIP) that were significantly higher or lower than those from SL-LIP-treated controls (P 0.05; one-way
ANOVA).
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similar to that induced by PR8 in mice depleted of airway
macrophages indicates that these cells play a critical role in
containing viral replication, inflammation, and disease. To-
gether, our data demonstrate a critical role for airway M in
modulating disease severity and indicate that the susceptibility
of particular virus strains to the antiviral responses of airway
M is likely to be an important factor contributing to their
virulence for mice.
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